Image Credit: depositphotos.com
Researchers from Queen Mary University of London, in collaboration with partners in India, have developed a groundbreaking oral cancer diagnostic test that promises to revolutionize patient monitoring. The test, known as the quantitative Malignancy Index Diagnostic System (qMIDS), utilizes a simple brush swab from the mouth to achieve diagnostic accuracy comparable to that of traditional surgical biopsies, but without the need for invasive procedures.
In a clinical trial involving 545 patients with potentially cancerous mouth lesions, the qMIDS test demonstrated an impressive overall accuracy rate of 95.5%. Both false-positive and false-negative rates were maintained at below five percent, as detailed in a study published in the journal Biomarker Research.
Oral cancer, which often manifests as persistent sores or discolored patches in the mouth, has seen a significant increase in cases worldwide—more than doubling since 1990. Early detection is critical for treatment, but traditional monitoring methods can be cumbersome and uncomfortable for patients. Standard biopsies are invasive and often require multiple procedures, leading many patients to skip necessary follow-ups.
The qMIDS test offers a non-invasive alternative. It analyzes mRNA expression from four specific genes associated with oral cancer using samples collected via a brush swab. A control swab is taken from a healthy area of the mouth to ensure accuracy. This third-generation system has shown remarkable effectiveness in distinguishing between cancerous and benign lesions.
The team behind qMIDS is currently working on commercializing the test, with expectations that it will be available for clinical use within the next two years. This innovation not only provides a more comfortable option for patients but also enables regular and systematic monitoring of pre-malignant lesions, thereby facilitating earlier detection of oral cancers.
Check out the original article here: Source link
